Canaccord Genuity Maintains Buy on Neuronetics, Lowers Price Target to $7
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst William Plovanic maintains Neuronetics (NASDAQ:STIM) with a Buy and lowers the price target from $8 to $7.
Canaccord Genuity analyst William Plovanic maintains Neuronetics (NASDAQ:STIM) with a Buy and lowers the price target from $8 to $7.